For research use only. Not for therapeutic Use.
Zonisamide（Cat No.:A000801）is an anticonvulsant medication primarily used to manage partial seizures in epilepsy. It works by blocking voltage-dependent sodium and calcium channels, stabilizing neuronal membranes, and reducing excessive neural firing. Additionally, zonisamide has mild inhibitory effects on carbonic anhydrase, contributing to its antiepileptic properties. Known for its broad spectrum, zonisamide is also being explored for mood stabilization and management of neurological disorders like Parkinson’s disease. Its once-daily dosing and generally favorable safety profile make it a valuable option in long-term epilepsy treatment and adjunctive therapy for seizure control.
| Catalog Number | A000801 |
| CAS Number | 68291-97-4 |
| Synonyms | CI-912; Zonegran; 1,2-Benzisoxazole-3-methanesulfonamide; 1,2-benzoxazol-3-ylmethanesulfonamide |
| Molecular Formula | C8H8N2O3S |
| Purity | ≥95% |
| Target | Calcium Channel |
| Solubility | >8.4mg/mL in DMSO |
| Storage | -20°C |
| Overview of Clinical Research | <span style=”font-size:12px;”>The phase IV study of Zonisamide on <span style=”caret-color: rgb(51, 51, 51); font-family: "Helvetica Neue", Helvetica, Arial, sans-serif;”> Parkinson's disease is completed. The phase I study of </span>Zonisamide on n<span style=”caret-color: rgb(51, 51, 51); font-family: "Helvetica Neue", Helvetica, Arial, sans-serif;”>eurological disorders and partial epilepsies is active. </span></span> |
| IUPAC Name | 1,2-benzoxazol-3-ylmethanesulfonamide |
| InChI | InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) |
| InChIKey | UBQNRHZMVUUOMG-UHFFFAOYSA-N |
| SMILES | C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N |
| Reference | 1: Zareba G. Zonisamide: review of its use in epilepsy therapy. Drugs Today (Barc). 2005 Sep;41(9):589-97. Review. PubMed PMID: 16341290.<br /> |
